Atticus Wealth Management LLC Grows Stock Position in Amgen Inc. (NASDAQ:AMGN)

Atticus Wealth Management LLC lifted its stake in shares of Amgen Inc. (NASDAQ:AMGNGet Rating) by 89.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 297 shares of the medical research company’s stock after purchasing an additional 140 shares during the quarter. Atticus Wealth Management LLC’s holdings in Amgen were worth $72,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the stock. IMS Capital Management raised its stake in shares of Amgen by 2.5% during the second quarter. IMS Capital Management now owns 2,353 shares of the medical research company’s stock worth $572,000 after purchasing an additional 57 shares during the last quarter. Private Advisor Group LLC raised its position in Amgen by 16.7% in the second quarter. Private Advisor Group LLC now owns 64,413 shares of the medical research company’s stock worth $15,672,000 after acquiring an additional 9,239 shares in the last quarter. Carnegie Capital Asset Management LLC raised its position in Amgen by 15.3% in the second quarter. Carnegie Capital Asset Management LLC now owns 79,699 shares of the medical research company’s stock worth $19,423,000 after acquiring an additional 10,579 shares in the last quarter. Vista Private Wealth Partners. LLC raised its position in Amgen by 11.2% in the second quarter. Vista Private Wealth Partners. LLC now owns 954 shares of the medical research company’s stock worth $231,000 after acquiring an additional 96 shares in the last quarter. Finally, Arlington Financial Advisors LLC raised its position in Amgen by 1.2% in the second quarter. Arlington Financial Advisors LLC now owns 27,440 shares of the medical research company’s stock worth $6,676,000 after acquiring an additional 317 shares in the last quarter. Hedge funds and other institutional investors own 77.14% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on AMGN. Atlantic Securities cut their price objective on Amgen from $190.00 to $182.00 and set an “underweight” rating for the company in a research report on Tuesday, August 9th. Robert W. Baird reiterated an “underperform” rating and issued a $185.00 price objective on shares of Amgen in a research report on Tuesday, September 13th. TheStreet upgraded Amgen from a “c+” rating to a “b” rating in a research report on Monday, August 15th. Morgan Stanley raised their price target on Amgen from $239.00 to $253.00 and gave the company an “equal weight” rating in a research report on Friday, July 15th. Finally, Oppenheimer restated an “outperform” rating and issued a $290.00 price target on shares of Amgen in a research report on Wednesday, September 14th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $241.13.

Insider Activity

In other news, Director Robert Eckert sold 6,600 shares of Amgen stock in a transaction on Thursday, August 18th. The stock was sold at an average price of $249.00, for a total transaction of $1,643,400.00. Following the transaction, the director now owns 21,184 shares in the company, valued at $5,274,816. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Amgen news, Director Robert Eckert sold 6,600 shares of the business’s stock in a transaction dated Thursday, August 18th. The stock was sold at an average price of $249.00, for a total value of $1,643,400.00. Following the transaction, the director now owns 21,184 shares in the company, valued at $5,274,816. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director R Sanders Williams sold 200 shares of the business’s stock in a transaction dated Monday, August 22nd. The shares were sold at an average price of $249.96, for a total value of $49,992.00. Following the completion of the transaction, the director now owns 5,301 shares in the company, valued at approximately $1,325,037.96. The disclosure for this sale can be found here. 0.46% of the stock is currently owned by corporate insiders.

Amgen Stock Down 1.4 %

AMGN opened at $224.46 on Thursday. Amgen Inc. has a one year low of $198.64 and a one year high of $258.45. The company has a debt-to-equity ratio of 14.76, a quick ratio of 1.17 and a current ratio of 1.53. The stock’s fifty day moving average is $243.76 and its 200-day moving average is $243.39. The company has a market capitalization of $120.07 billion, a PE ratio of 19.02, a P/E/G ratio of 1.86 and a beta of 0.56.

Amgen (NASDAQ:AMGNGet Rating) last announced its earnings results on Thursday, August 4th. The medical research company reported $4.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.40 by $0.25. The company had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.53 billion. Amgen had a return on equity of 218.34% and a net margin of 24.92%. Amgen’s revenue for the quarter was up 1.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $4.38 earnings per share. On average, equities analysts predict that Amgen Inc. will post 17.45 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 8th. Stockholders of record on Thursday, August 18th were issued a dividend of $1.94 per share. The ex-dividend date was Wednesday, August 17th. This represents a $7.76 dividend on an annualized basis and a dividend yield of 3.46%. Amgen’s dividend payout ratio is 65.76%.

Amgen Company Profile

(Get Rating)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

See Also

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNGet Rating).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.